Introduction:
Draft Scheme of Amalgamation has been approved to streamline operations and enhance shareholder value. The merger awaits regulatory, statutory, and shareholder approvals, aligning with legal provisions. This move aims to bolster market presence and improve operational efficiency for the entities involved.
Share price movement of Gujarat Themis Biosyn Ltd:
On November 19, 2024, Gujarat Themis Biosyn Ltd. opened at ₹313.00, a 2.69% increase from its previous close of ₹304.80. The stock reached an intraday high of ₹339.90, up 11.50%, and an intraday low of ₹312.00, rising 2.36%.
By 12:22 PM, it was trading at ₹327.00, reflecting a 7.28% increase. The market capitalization for the day stood at ₹3,563.16 crore.
Gujarat Themis Biosyn and Themis Medicare Announce Amalgamation Plan
In a significant move, the Boards of Gujarat Themis Biosyn Limited and Themis Medicare Limited approved a draft Scheme of Amalgamation on November 18, 2024. The merger is subject to approvals from secured creditors, shareholders, stock exchanges, SEBI, NCLT, and other relevant regulatory bodies.
This strategic merger aims to consolidate operations, integrating the entire product value chain into a unified entity. The move is expected to generate significant synergies, enhancing operational efficiencies and strengthening market positioning for both companies.
Under the approved scheme, TML will issue 118 equity shares for every 100 equity shares held by GTBL shareholders. These shares will be fully paid-up with a face value of Re. 1 each.
Also Read: Smallcap stock jumps 15% after company forays into EV and Li-ion battery assembly
Recent news on Gujarat Themis Biosyn Ltd:
As of November 19, 2024, Gujarat Themis Biosyn Ltd recently announced their Q2 results. The company reported a 12.45% decline in standalone net sales for the September 2024 quarter, falling to ₹34.72 crore from ₹39.65 crore in the same period last year. The decline reflects challenging market conditions.
Stock performance of Gujarat Themis Biosyn Ltd for Period of 1 week, 6 months and 1 year:
Gujarat Themis Biosyn Ltd recorded a one-week return of -3.92%, reflecting short-term market fluctuations. Over six months, the stock achieved a 16.9% return, showcasing steady growth. Over one year, it delivered an impressive 151% return, highlighting significant long-term performance.
Also Read: FMCG stock hits 20% lower circuit after it reports huge losses in Q2 FY25
Shareholding pattern of Gujarat Themis Biosyn Ltd:
| All values in % | Sep 2024 | Jun 2024 | Mar 2024 |
| Promoter | 70.90% | 70.90% | 70.90% |
| FII | 1.50% | 1.40% | 1.10% |
| DII | 1.20% | 1.20% | 0.80% |
| Public | 26.50% | 26.50% | 27.30% |
About the company Gujarat Themis Biosyn Ltd:
Gujarat Themis Biosyn Ltd (GUJTHEM | 506879 | INE942C01045), established in 1981, specializes in manufacturing Active Pharmaceutical Ingredients through fermentation. Known for Rifamycin-based products, it operates a Vapi plant with 16,000 kg/month capacity and is expanding its API and R&D capabilities, targeting completion by FY26.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
